About Pharmasaga
Pharmasaga (hereinafter referred to as "the Company") was established on January 25th, 2021, as a clinical drug development company. It is comprised of an experienced management team, a top-tier technical team, and a diverse group of specialized consultants. The Company aims to promote Taiwan's novel drug research and development to the global stage.
The Company's core technology is exclusively licensed from years of research by its founder, Dr. Wen-Ching Yang, encompassing world-leading assets: a proprietary diabetes drug screening platform and a first-in-class small-molecule drug product. Our business strategy is to target the billion-dollar diabetes market by developing a novel small-molecule drug (505(b)(1)) with a unique mechanism of action, securing a competitive advantage to drive company profitability and growth.
The Company's development strategy has evolved from an initial No Research, Development Only (NRDO) model to a model that emphasizes both Research and Development (R&D). We focus on novel drugs with short development cycles and high profitability. By controlling the most crucial patents, technology, management/R&D teams, and resources, and collaborating with consultants of different expertise, we commission manufacturing and clinical trials to external professional vendors. This division of labor allows us to achieve various milestones with minimal resources and maximum efficiency.
Our competitive edge is a single drug with multiple indications and a flexible, effective clinical strategy. We leverage professional clinical development to rapidly enter the market and achieve early profitability.
Our vision is to develop the world's first small-molecule drug for diabetes with a novel mechanism that can treat and reverse the disease, ultimately aiming to end diabetes and its complications and enhance the well-being of all humanity.
